Top

Published in:

01-03-2006 | Original Article

Improved Staging With Pretreatment Positron Emission Tomography/Computed Tomography in Low Rectal Cancer

Authors: Susan L. Gearhart, MD, Deborah Frassica, MD, Ron Rosen, MD, Michael Choti, MD, Richard Schulick, MD, Richard Wahl, MD

Published in: Annals of Surgical Oncology | Issue 3/2006

Abstract

Background

¹⁸F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT) are widely accepted in the evaluation for metastatic or recurrent rectal cancer. Only spiral CT and transrectal ultrasonography (TRUS) are routinely used in the initial evaluation of primary rectal cancer. We wished to determine whether PET/CT could provide additional information in patients undergoing standard evaluation for primary rectal cancer.

Methods

Thirty-seven patients (mean age, 58 years; range, 26–90 years) with a previously untreated rectal cancer underwent TRUS or magnetic resonance imaging, spiral CT, and FDG-PET/CT. The tumor location (low, ≤6 cm; mid, 7–10 cm; or high, ≥10 cm) and carcinoembryonic antigen level were recorded. Discordant findings between spiral CT and FDG-PET/CT were confirmed by histological analysis or imaging follow-up.

Results

FDG-PET/CT identified discordant findings in 14 patients (38%), and this resulted in upstaging of 7 patients (50%) and downstaging of 3 patients (21%). Although node-positive disease on TRUS/magnetic resonance imaging was associated with discordant FDG-PET/CT findings, this was not statistically significant. Discordant PET/CT findings were significantly more common in patients with a low rectal cancer than in those with mid or high rectal cancer (13 vs. 1; P = .0027). The most common discordant finding was lymph node metastasis (n = 7; 50%). Histological confirmation of discordant FDG-PET/CT findings was performed in seven patients, and in no case did FDG-PET/CT prove to be inaccurate. Discordant PET/CT findings resulted in a deviation in the proposed treatment plan in 27% of patients (n = 10).

Conclusions

FDG-PET/CT frequently yields additional staging information in patients with low rectal cancer. Improved accuracy of pretreatment imaging with FDG-PET/CT will allow for more appropriate stage-specific therapy.

Colon Cancer Facts and Figures, American Cancer Society Annual Report, Special Edition, 2005. Available: http://www.cancer.org/docroot/home/index.asp [accessed January 17, 2006]

Schaffzin DM, Wong WD. Endorectal ultrasound in the preoperative evaluation of rectal cancer. Clinical Colorectal Cancer 2004;4:124–32PubMed

Zerhouni EA, Rutter C, Hamilton SR, et al. CT and MRI imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II. Radiology 1996;200:443–51PubMed

Staib L, Schirmeister H, Reske SN, et al. Is 18F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000;180:1–5CrossRefPubMed

Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computerized tomography. Ann Surg Oncol 1997;4:613–20CrossRefPubMed

Even-Sapir E, Parag Y, Lerman H, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004;232:815–22PubMed

Guillem JG, Moore HG, Akhurst T, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining long-term outcomes of rectal cancer. J Am Coll Surg 2004;199:1–7CrossRefPubMed

Calvo FA, Domper M, Matute R, et al. ¹⁸F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004;58:528–35CrossRefPubMed

Green F, Page K, Flemming I, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002:113–23

10.

Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365–71CrossRefPubMed

11.

Winawer SJ, Flehinger BJ, Schottenfeld D, Meller DG. Screening for colorectal cancer by fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993;85:1311–8PubMed

12.

Fisher B, Wlmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP Protocol R-01. J Natl Cancer Inst 1988;80:21–9PubMed

13.

Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000;92:388–96CrossRefPubMed

14.

Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980–7CrossRef

15.

Kapiteijn E, Marijnen C, Nagtegaal I, et al. Preoperative radiotherapy combined with total mesorectum excision for resectable rectal cancer. N Engl J Med 2001;345:638–46CrossRefPubMed

16.

Heriot AG, Hicks RJ, Drummond EG, et al. Does positron emission tomography change management in primary rectal cancer? A prospective assessment. Dis Colon Rectum 2004;47:451–8CrossRefPubMed

17.

Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002;45:200–6CrossRefPubMed

18.

Habr-Gama A, Perez RO, Nadalin W, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005;9:90–101PubMed

19.

Enker WE, Thaler HT, Cranor ML, et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995;181:335–46PubMed

20.

Adam IJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994;344:707–11CrossRefPubMed

21.

Morita T, Murata A, Koyama M, et al. Current status of autonomic nerve-preserving surgery for mid and lower rectal cancer: Japanese experience with lateral node dissection. Dis Colon Rectum 2003;46:S78–87PubMed

22.

Hasdemir O, Col C, Yalcum E, et al. Local recurrence and survival rates after extended systematic lymph-node dissection for surgical treatment of rectal cancer. Hepatogastroenterology 2005;52:455–9PubMed

23.

Ciernik FI, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853–63CrossRefPubMed

24.

Mendenhall WM, Bland KI, Copeland EM, et al. Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? Ann Surg 1992;215:696–705PubMed

25.

Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 2000;284:1008–15CrossRefPubMed

Title: Improved Staging With Pretreatment Positron Emission Tomography/Computed Tomography in Low Rectal Cancer
Authors: Susan L. Gearhart, MD
Deborah Frassica, MD
Ron Rosen, MD
Michael Choti, MD
Richard Schulick, MD
Richard Wahl, MD
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 3/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2006.04.042

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Improved Staging With Pretreatment Positron Emission Tomography/Computed Tomography in Low Rectal Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2006

The Growing Pains of Neoadjuvant Trials for Gastroesophageal Carcinoma

Laparoscopic Versus Open Surgery for Rectal Cancer: A Meta-Analysis

Sentinel Lymph Node Mapping of the Gastrointestinal Tract by Using Invisible Light

Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases

A Pathologic Assessment of Adequate Margin Status in Breast-Conserving Therapy

The Promises and Potential Pitfalls of Organ Preservation for Locally Advanced Rectal Cancer